Section Arrow
BDTX.NASDAQ
- Black Diamond Therapeutics
Quotes are at least 15-min delayed:2025/07/25 04:21 EDT
Pre Market
Last
 3.22
+0.1 (+3.21%)
Bid
3.12
Ask
3.26
High 3.22 
Low 3.12 
Volume 5187 
Regular Hours
Last
 3.12
-0.07 (-2.19%)
Day High 
3.225 
Prev. Close
3.19 
1-M High
3.315 
Volume 
560.94K 
Bid
3.12
Ask
3.26
Day Low
3.115 
Open
3.19 
1-M Low
2.275 
Market Cap 
181.39M 
Currency USD 
P/E 52.67 
%Yield -- 
10-SMA 3.04 
20-SMA 2.78 
50-SMA 2.45 
52-W High 6.75 
52-W Low 1.195 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.06/-1.32
Enterprise Value
200.17M
Balance Sheet
Book Value Per Share
2.49
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.054+0.0014+2.66%-- 
Pre Market 0.0549 +0.0009 +1.67%
TNFATNF Pharmaceuticals Inc.0.132+0.0199+17.75%-- 
Pre Market 0.1235 -0.0085 -6.44%
PSTVPlus Therapeutics0.5965+0.1065+21.73%-- 
Pre Market 0.5929 -0.0036 -0.60%
SRPTSarepta Therapeutics12.88-0.44-3.30%15.76PE
Pre Market 12.23 -0.65 -5.05%
IOVAIovance Biotherapeutics3.29-0.68-17.13%-- 
Pre Market 3.41 +0.12 +3.65%
Quotes are at least 15-min delayed:2025/07/25 04:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.